[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368158-105":59,"doc-detail-368158-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","understanding-the-role-of-metabolic-syndrome-in-prostate-cancer-risk-a-uk-biobank-prospective-cohort-study","Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study","","Predictive value of metabolic syndrome for prostate cancer risk is unclear. This prospective UK Biobank cohort study assessed associations between metabolic syndrome and its components with prostate cancer incidence. Prostate cancer incidence was modeled using flexible parametric survival approaches, producing incidence rate ratios and adjusted cumulative incidence curves. Among 242,349 men followed to 2021, 6,467 cases occurred. Metabolic syndrome overall was not linked to risk, whereas hypertension and obesity increased risk. Prediabetes/diabetes and low cholesterol were associated with reduced risk, while hyperlipidaemia showed no significant effect.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/understanding-the-role-of-metabolic-syndrome-in-prostate-cancer-risk-a-uk-biobank-prospective-cohort-study/368158/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/understanding-the-role-of-metabolic-syndrome-in-prostate-cancer-risk-a-uk-biobank-prospective-cohort-study/368158.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary objective of this study?","Question",{"text":113,"@type":114},"To evaluate the association between metabolic syndrome and each of its components with prostate cancer incidence.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was prostate cancer incidence analyzed in the UK Biobank cohort?",{"text":118,"@type":114},"Using flexible parametric survival models to derive incidence rate ratios and adjusted cumulative incidence curves.",{"name":120,"@type":111,"acceptedAnswer":121},"Did metabolic syndrome as a whole increase prostate cancer risk?",{"text":122,"@type":114},"No. Metabolic syndrome overall was not associated with prostate cancer risk.",{"name":124,"@type":111,"acceptedAnswer":125},"Which metabolic syndrome components showed increased or decreased risk?",{"text":126,"@type":114},"Hypertension and obesity increased risk, while prediabetes/diabetes and low cholesterol were associated with reduced risk; hyperlipidaemia had no significant effect.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},368158,1790211982,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nUnderstanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study  \nShing Fung Lee1,2, Maja Nikšić3 & Miguel Angel Luque-Fernandez4,5􀀍  \nPredictive value of metabolic syndrome for prostate cancer risk is not clear. We aimed to assess the association between metabolic syndrome and its components with prostate cancer incidence. The primary outcome was prostate cancer incidence, i.e., incidence rate ratios and adjusted cumulative incidence curves derived from flexible parametric survival models. Adjusted cumulative incidence curves were derived using a flexible survival parametrical modeling framework. We analysed UK Biobank data including 242,349 adult males, recruited during 2006–2010 and followed up until 2021, during which 6,467 (2.7%) participants were diagnosed with prostate cancer. Our findings indicate that metabolic syndrome, as a whole, was not associated with prostate cancer risk (incidence rate ratios, 1.07; 95% confidence interval, 0.94–1.22) . However, specific components such as hypertension and obesity increased the risk (incidence rate ratios, 1.22; 95% confidence interval, 1.03–1.44 and incidence rate ratios, 1.24; 95% confidence interval, 1.05–1.46, respectively). Other components, such as prediabetes/diabetes and low cholesterol, were associated with a reduced risk (incidence rate ratios, 0.80; 95% confidence interval, 0.67–0.94 and incidence rate ratios, 0.82; 95% confidence interval, 0.69–0.97, respectively), while hyperlipidaemia showed no significant effect (incidence rate ratios, 1.07; 95% confidence interval, 0.93–1.24) . Further research is needed to understand the underlying mechanisms behind these relationships. Prostate cancer prevention strategies might benefit from targeting modifiable risk factors, particularly hypertension and obesity.  \nKeywords Prostate Cancer, Metabolic Syndrome, Risk Factors, Lifestyle, Diet, Exercise  \nProstate cancer is the fourth most commonly diagnosed cancer worldwide and is the eighth leading cause of cancer-related deaths among men globally1. In the UK, the prostate cancer incidence rates have risen since the 1990s, increasing notably from around age 45 and peaking in the 75–79 age group2. During the last decade (between 2007–2009 and 2017–2019), age-standardised prostate cancer incidence rates increased by 9% in the UK2. This aligns with increasing trends observed in other high-income regions, including the US, Canada, Europe, and Australasia; with a steady rate of average increase of 2% per year globally, since 19903.  \nThe rising incidence underscores the need to re-examine potential risk factors for prostate cancer and develop effective preventive strategies. Established non-modifiable risk factors include older age, ethnicity, Black race, family history of prostate cancer, and certain genetic polymorphisms4,5. Conversely, metabolic syndrome is considered a modifiable risk factor6. Although the extent to which it can be effectively managed or reversed depends on individual factors such as overall health and lifestyle changes.  \nMetabolic syndrome is a cluster of interconnected anthropometrical and biochemical risk factors and metabolic diseases, including hypertension, high triglyceride, central obesity, low high-density lipoprotein-cholesterol, and prediabetes/diabetes7. Given the current lifestyle trends leading to increasing obesity8, hypertension9, and prediabetes/diabetes10, the prevalence of metabolic syndrome is projected to continue to rise, especially in most developed countries and some developing countries11, 12. Previous studies often considered metabolic syndrome as a combined entity due to the frequent co-occurrence and interdependence of its individual components,  \n1Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore. 2Department of Medicine, Yong Loo Lin Scho","cbCaiqiyaUa8eW67","https://ap.wps.com/l/cbCaiqiyaUa8eW67","pdf",1419781,"English","# Study Background\n## Rationale for Reassessing Risk Factors\n## Metabolic Syndrome as a Modifiable Risk Cluster\n# Methods and Materials\n## Study Population and Case Definition\n## Outcome Modeling and Statistical Approach\n# Findings\n## Overall Association of Metabolic Syndrome\n## Component-Level Associations","[{\"question\":\"What was the primary objective of this study?\",\"answer\":\"To evaluate the association between metabolic syndrome and each of its components with prostate cancer incidence.\"},{\"question\":\"How was prostate cancer incidence analyzed in the UK Biobank cohort?\",\"answer\":\"Using flexible parametric survival models to derive incidence rate ratios and adjusted cumulative incidence curves.\"},{\"question\":\"Did metabolic syndrome as a whole increase prostate cancer risk?\",\"answer\":\"No. Metabolic syndrome overall was not associated with prostate cancer risk.\"},{\"question\":\"Which metabolic syndrome components showed increased or decreased risk?\",\"answer\":\"Hypertension and obesity increased risk, while prediabetes/diabetes and low cholesterol were associated with reduced risk; hyperlipidaemia had no significant effect.\"}]","Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study | PDF",1790175338,25,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/379ba0317a8715a8b03af16e1ce260c1.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4972ab83add6b5a3ad62ca015f979ed6.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97db8e33caf5cc8c9beea7dddd0b7967.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9079995bc4d47e004ed4882f4abb81e.webp",980,1287]